GlassScriptPhysician profile
Eneida Depina
NPI 1528303468
$1,253.53
in general payments reported to CMS, 2019-2025
21 companies · $298 in 2025
The $298 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $287 · 2022: $157 · 2023: $223 · 2024: $289 · 2025: $298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $809.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $157.84 | 2021 | |
| Abbvie INC. | $150.39 | 2021-2023 | |
| Exeltis, USA INC. | $122.27 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $101.08 | 2021-2025 | |
| Astellas Pharma US INC | $97.66 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $90.11 | 2023-2025 | |
| Organon LLC | $71.55 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $64.43 | 2021-2025 | Gardasil 9, Gardasil |
| Agile Therapeutics, INC. | $62.57 | 2023-2024 | Twirla |
| Coopersurgical, INC. | $46.87 | 2022-2025 | Paragard T 380a |
| Glaxosmithkline, LLC. | $46.57 | 2021-2025 | Bexsero, Arexvy, Shingrix |
| Hologic Sales and Service, LLC | $35.03 | 2024 | Aptima |
| Sumitomo Pharma America, INC. | $33.94 | 2023-2025 | Myfembree |
| Evofem Biosciences, INC. | $31.05 | 2022-2024 | |
| Avion Pharmaceuticals | $29.86 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $27.41 | 2024 | Stratafix |
| Sage Therapeutics, LLC | $19.31 | 2024 | |
| Millicent US INC | $17.54 | 2025 | Femlyv |
| Olympus America INC. | $16.98 | 2024 | |
| Therapeuticsmd, INC. | $16.07 | 2022 | |
| Mylan Pharmaceuticals INC. | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eneida Depina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.